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BICUSPID AORTIC VALVE (BAV) is the most common congenital cardiovascular malformation, affecting 1.3% of the general population (21, 30) . BAV is an important risk factor for aortic valve disease and ascending aortic aneurysm (6, 21, 26) . Premature valvular degeneration and consequent valve dysfunction is the most common complication of BAV disease and is responsible for up to one-third of aortic valve replacements in the Western world (19 -21) . Valve dysfunction in BAV ranges from predominantly stenotic lesions with heavy valve calcification and/or fibrosis to predominantly regurgitant lesions with leaflet prolapse, fibrotic retraction, malcoaptation from aortic root dilatation, or leaflet destruction from infective endocarditis. Furthermore, while BAV underlies 70%-85% of aortic valve stenosis in children and over 50% of aortic stenosis in adults (6) , different pathological processes appear to be present.
In newborn infants or young children, BAV-related stenosis is a consequence of thickened leaflets with severe restriction in valve orifice opening (30, 31) , probably signifying a more severe disorder of aortic valvulogenesis. During adulthood, premature leaflet sclerosis and calcific degeneration from the abnormal hemodynamic shear stress are likely to be responsible for BAV-related stenosis (30, 31) . In contrast, although any degree of aortic regurgitation can be detected in up to 59% of community cohort with BAV during echocardiography, intervention for isolated severe aortic incompetence is relatively uncommon in BAV, affecting only 3-7% of patients (19, 21, 32) . This highlights the wide spectrum of clinical manifestation and outcome of valvular degeneration and dysfunction in BAV. Detection of BAV-related valvular degeneration is important, as it is an independent predictor of long-term cardiovascular events, including aortic valve surgery and cardiac death, even in patients with normally functioning BAV at baseline (20) .
A high heritability rate and familial clustering strongly imply that BAV has an underlying genetic basis (6) . In humans, mutations of the transcription factor NOTCH1 [Notch homolog 1, translocation-associated (Drosophila)] gene are associated with limited cases of familial and sporadic BAV, as well as aortic valve calcification, possibly as a result of derepression of RUNX2 (runt-related transcription factor 2), a downstream transcriptional regulator of osteoblast cell fate (11) . Recently, the presence of rare nonsynonymous variations within the conserved transcriptional activator domains of GATA5 (GATA binding protein 5), a transcription factor essential to cardiac and aortic valve development, was reported in patients with BAV (25) . Additionally, orchestrated regulation of gene transcription is essential during cardiac development and valvulogenesis, and disruption to this process likely contributes to various cardiac pathologies, including BAV. Microarray profiling of microRNA regulators of gene expression highlighted reduced expression of miR-26a, miR-30b, and miR-195 in stenotic BAV associated with calcification compared with a regurgitant BAV phenotype (24) . These microRNAs were shown to modulate the mRNA levels of several calcificationrelated genes in vitro (24) . Furthermore, exon microarray profiling has revealed altered gene expression and mRNA splicing in the myocardium of patients with hypoplastic left heart syndrome, a condition that is genetically related to BAV disease (12, 28) . Despite these recent insights, the molecular mechanism underlying the development of phenotype heterogeneity of valvular degeneration in BAV disease, however, remains incompletely understood.
The tissue transcriptome contains the entire repertoire of all transcripts expressed in a given tissue of an organism. Transcriptome analysis using next-generation sequencing technologies [RNA sequencing (RNA-seq)] is becoming a preferred method of choice over hybridization-based microarray profiling (16) . Advantages of RNA-seq include a large dynamic range of expression levels that is not affected by on-chip sequence biases, low background signal due to perfect matching of sequencing reads, single base resolution of transcription boundaries, and the relatively small amount of total RNA required for quantification compared with microarray (16) . In the current study, we sought use RNA-seq to profile and compare the transcriptomes of noncalcified, primarily regurgitant BAV, and calcified, primarily stenotic BAV subtypes with calcified stenotic (degenerative) tricuspid aortic valves (TAV) and to identify molecular pathways involved in valve degeneration in BAV disease.
MATERIALS AND METHODS

Study population and aortic valve collection.
Patients with BAV or TAV, referred for aortic valve or aortic root surgery at the Royal Prince Alfred Hospital, Sydney, Australia, were prospectively recruited from May to December 2012. Patients with a history of rheumatic heart disease, infective endocarditis, or connective tissue disorders were excluded. All patients underwent clinical evaluation that included family history and preoperative two-dimensional echocardiography where the morphology and functional state of the aortic valve was determined according to the American Heart Association and the American College of Cardiology guidelines (1) . The aortic valve morphology and the presence of valvular degeneration, as signified by the extent of leaflet calcification, thickening, prolapse, and/or redundancy, were documented at surgery. Calcification was graded mild (Ͻ1/3 leaflet area affected) or severe (Ͼ2/3 leaflet area affected). Immediately following surgical removal, a portion of the aortic valve leaflet was immersed in RNAlater solution (Ambion, Austin, TX) overnight and stored at Ϫ80°C.
All patients gave written informed consent, and the study was approved by the Sydney South West Area Health Service Ethics Committee (protocol no. X10-0083, HREC/10/RPAH/157).
RNA isolation. Total valve RNA was isolated with TRIzol reagent (Invitrogen, Life Technologies), according to the manufacturer's instruction. RNA purity, concentration, and integrity were evaluated by a combination of Nanodrop 2000 spectrophotometer (Thermo Scientific), 2100 Bioanalyzer (RNA6000 Nano LabChip; Agilent Technologies, Santa Clara, CA), and/or agarose gel electrophoresis.
RNA-seq and gene expression analysis. RNA-seq was performed on eight male, DNase I-treated RNA samples having RNA integrity number (RIN) Ն 7 (3 TAV, 5 BAV) (BGI Facility, Hong Kong). Illumina TruSeq RNA-seq library (Illumina, San Diego, CA) was prepared on 5 g total RNA according to the manufacturer's *Degree of leaflet calcification, ranging from ϩϩϩ for heavily calcified leaflets (Ͼ2/3 leaflet area affected), ϩ for very mild calcification (Ͻ1/3 area affected) to Ϫ for no calcification; †ascending aortic size was graded as normal (Ͻ38 mm) or mildly (38 mm to Ͻ45 mm), moderately (45 mm to Ͻ50 mm), or severely (Ն50 mm) dilated; AV, aortic valve; TAV, tricuspid aortic valve; BAV, bicuspid aortic valve; M, male; R-L, right and left; AS, aortic stenosis; AR, aortic regurgitation; n/a, not applicable.
instructions, and 100 base paired-end sequenced on a HiSeq2000 (Illumina). FASTQ files were aligned to the human reference sequence (NCBI GRCh37/hg19) using Bowtie and TopHat2 v2.0.6 (15) with a transcriptome-index to guide mapping of splice junction-spanning reads (ftp://ftp.ensembl.org/pub/release-73/gtf/ homo_sapiens/Homo_sapiens.GRCh37.73.gtf.gz). Aligned reads in BAM format were annotated against the protein-coding mRNA regions. SeqMonk v.0.24.1 platform (Babraham Bioinformatics, Cambridge, UK) was utilized to visualize the annotated/mapped read, quantify data (using corrected log 2 transformed Reads Per Million Values of nonstrand specific, unmerged isoform), and perform percentile normalization. An intensity difference analysis method (4) was used to identify differentially expressed genes (DEGs) on the normalized quantification data. A gene was classified as up-or downregulated using a cut-off value of more or less than 1.5-fold expression difference, respectively, between BAV vs. TAV, with an adjusted P value Ͻ0.05, following post hoc Bonferroni correction. A small number of unannotated genes with uncharacterized protein were excluded from subsequent analysis.
SeqMonk was also utilized to perform hierarchical clustering and heat map analysis of DEGs. Ingenuity Pathway Analysis (IPA) and PANTHER (http://www.pantherdb.org) were used to assess biological networks and pathways connected to the DEGs. Gene Ontology (GO)-based enrichment and KEGG pathway analysis of DEGs were performed against a background list of global aortic valve proteincoding mRNAs expression, using the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resources (version 6.7, National Institutes of Health). Enrichment score of Ն1.3 and Benjamini-Hochberg corrected P value Ͻ0.05 were used as a cut-off for significance. Statistical analysis. Normally distributed data were reported as means Ϯ standard deviation (SD). Statistical evaluation of parametric data was performed with a two-tailed unpaired Student's t-test using Welch's correction for data with unequal variance. Statistical analysis of RT-qPCR data was performed on the normalized relative expression level using the Kruskal-Wallis test with post hoc Dunn's test for three-group comparison and a Mann-Whitney unpaired t-test for two-group comparison. A P Ͻ 0.05 was considered statistically significant. Statistical analyses were performed with GraphPad Prism v.6.0b (GraphPad Software, La Jolla, CA).
RESULTS
Between May and December 2012, aortic valve leaflets from 36 unrelated patients were collected and their RNA extracted. Nine of these RNA samples were excluded because of poor quality (i.e., degraded RNA), thus leaving 27 suitable total RNAs (from 21 BAV and 6 TAV samples) for RT-qPCR analysis (Fig. 1 ). Of these, 5 BAV and 3 TAV RNA samples with a RIN Ͼ7.0 underwent RNA-seq analysis. Clinical characteristics of the eight patients comprising the RNA-seq cohort are described in Table 1 . All were males and predominantly Caucasian. The three TAV patients had severe calcific (degenerative) aortic stenosis and were significantly older at surgery *IPA score is based on a P value calculation, representing the likelihood that the differentially expressed genes are part of a network therein by random chance alone. Mathematically, the score is the negative exponent of the right-tailed Fisher's exact test.
(71 Ϯ 8 yr vs. 53 Ϯ 12 yr, P ϭ 0.038) compared with the BAV patients, of which two had severe calcific aortic stenosis, one had mild aortic stenosis, and two had moderate or severe aortic regurgitation.
Differential gene expression profiling in BAV and TAV. Global gene expression levels of BAV (n ϭ 5) and TAV (n ϭ 3) demonstrated significant correlation (Pearson's R ϭ 0.992, Fig. 2) . Intensity difference analysis revealed differential expression of 1,102 probe sets, corresponding to 59 and 177 genes, that were significantly up-or downregulated, respectively, in BAV (Table 2, full list in Supplementary Table  S1) . 1 Notably, seven of the 10 most significantly up-and downregulated genes were involved in extracellular matrix production and degradation, namely matrix metalloproteinases 13 and 9 (MMP13, MMP9), LAMC3 (laminin, gamma 3), CHAD (chondroadherin), IBSP (integrin-binding sialoprotein), COL11A1 (collagen, type 11␣1), and SPP1 (osteopontin).
Among these 236 DEGs, IPA identified four major biological networks whose functions were broadly involved in connective tissue disorders, tissue morphology, cardiovascular system development and function, immune cell trafficking, and cell-to-cell signaling and interaction (Table 3) . Exploration of GO-related terms similarly revealed overrepresentation of extracellular matrix component and biological processes involving inflammatory response, ossification, homeostatic, and collagen metabolic process (Table 4) . Specific biological functions most significant to the DEGs and considered to be pertinent to BAV development and aortic valve degeneration, including calcium signaling, connective tissue development, fibrosis, and proteolysis, are presented in Supplementary Table S2 .
Hierarchical clustering and heat mapping of the DEGs indicated differences in the overall gene expression between BAV and TAV (Fig. 3) . Furthermore, heterogeneity within the BAV group was apparent as distinct expression patterns separated BAV patients with leaflet redundancy/prolapse and no more than mild leaflet calcifications (BAVr) from patients with heavily calcified BAV leaflets (BAVc). Expression pattern of BAVc group appeared to be an "intermediate pattern" that more resembled the TAV group (particularly sample BAV5) and in some contrast to BAVr. Closer inspection of quantitative data of DEG expression within each individual samples further supported this observation (data not shown).
Comparative analyses of DEGs in subgroups. Given the heterogeneity observed within the BAV group during hierarchical clustering and heat map analysis, DEGs were evaluated between the different combinations of subgroup pair, i.e., BAVr vs. TAV, BAVr vs. BAVc, and BAVc vs. TAV. Overall, BAVc vs. TAV group analyses yielded the smallest number of DEGs (Fig. 4) with a narrower range in the degree of foldchange in gene expressions compared with the other two subgroup pairs. Eighty out of 193 DEGs (41%) in BAVc vs. TAV group had less than twofold change in their mRNA expression level, while none of the 265 DEGs in BAVr vs. BAVc group and only one out of 224 DEGs (0.4%) in BAVr vs. TAV group had a similar degree of alteration (Supplementary Tables S3-S5 ). Comparison of extracellular matrix, calcification, and cardiac-related genes of interest (including genes that may play a role during cardiac development), randomly selected from the overall BAV vs. TAV comparison (Supplementary Table S1 ), revealed similar trends in the direction of change (up-or downregulation) and the degree of fold change in BAVr vs. BAVc and BAVr vs. TAV group. Dysregulation of these genes was less notable in the BAVc vs. TAV group. 1 The online version of this article contains supplemental material. These observations suggest that BAVc expression pattern was more similar to the TAV rather than the BAVr group. Analyses of GO-related terms enrichment clusters from the different comparative subgroup analyses revealed dysregulation of extracellular matrix genes and focal adhesion-related genes to be a common feature of valvular degeneration among the three comparative subgroups (Supplementary Tables S6A,  S6B , and S6C). Meanwhile, ossification and inflammatory response gene cluster overexpression were notable in both BAVc and TAV compared with the BAVr.
Validation of RNA-seq data. Total RNA isolated from 31 aortic valve leaflet preparations obtained from 27 unrelated patients, including the eight samples used in the RNA-seq experiment, was included in the RT-qPCR validation study and analyzed simultaneously with two overarching aims: first, to provide technical validation of the RNA-seq findings by validating a subset of DEGs of interest by RT-qPCR using the same RNAs used in the RNA-seq experiments; second, to provide biological validation of the RNA-seq findings by performing RT-qPCR on the same selection of genes of interest using RNAs from different patients. The results obtained from the validation experiments were then extrapolated to the remaining nonvalidated genes. We analyzed RT-qPCR validation data by comparing the gene expression level among the TAV, BAVr, and BAVc subgroups.
Clinical characteristics of the validation groups are summarized in Table 5 . The validation groups consisted of 8, 10, and 13 total valve RNA samples obtained from 6 TAV, 9 BAVr, and 12 BAVc patients, respectively, the majority of whom were male and of Caucasian background. In two BAV and two TAV patients in whom excess aortic valve leaflet tissues were available, two total RNA preparations were made from each patient, extracted from different parts of the leaflets, and treated as separate samples to maximize the number of total RNA available for statistical analysis.
From the randomly selected genes of interest, nine extracellular matrix and calcification-related genes that were up-and Overall, RT-qPCR analyses validated the differential expression between BAVr vs. TAV on all of the selected genesof-interest (Fig. 5) . RT-qPCR also validated the differential expression of five of these genes (ACAN, COL6A6, LAMC3, MMP13 and MMP7) in the BAVr compared with BAVc group. RNA-seq, however, found no significant difference in the expressions of CHI3L1, COL6A6, IBSP, LAMC3, and MMP13 in the BAVc vs. TAV group, and these too were verified by RT-qPCR analysis. This indicates relatively good agreement between the RNA-seq and the RT-qPCR results.
Identification of shared and unique pathways. To identify unique and common genes that were important in the pathogenesis of valvular degeneration among subgroups, we used the DEG gene list specific to different subgroup pairs to construct a Venn diagram (Fig. 6 , full gene list in Table 6 ). The rationale was that DEGs between the BAVr vs. TAV group would consist of genes that were responsible for not only BAV leaflet redundancy/prolapse or calcification in TAV but also BAV development, while BAVr vs. BAVc comparison would highlight genes responsible for the different form of valvular 
R-N fusion (1) True BAV (2) true BAV (2) Predominant valve dysfunction (patients, n)
severe AS (6) moderate or severe AR (6) severe AS (12) mild AR* (2) mild AS* (1) *Surgically unsuitable for either repair or preservation; †when residual sample was available, RNA was extracted from a different portion of the leaflet and used for validation analysis; BAVr, bicuspid aortic valve with leaflet redundancy and either no calcification or minimal calcification; BAVc, BAV with severe valve calcification; BAV morphology: R-L fusion, functionally bicuspid due to fusion of right and left coronary leaflets; R-N fusion, functionally bicuspid due to fusion of right and noncoronary leaflets, true BAV, anatomically bicuspid with 2 equal sized leaflets and the absence of raphe. In 7 out of 9 BAVr samples, amplicon of correct size had failed to be amplified in 2 independent experiments, suggesting negligible expression of MMP13 in these samples, which supports the RNA-seq findings. *P Ͻ 0.05; **P Ͻ 0.005; ***P Ͻ 0.0005, P value assessed by Mann-Whitney 2-tailed t-test. degeneration in BAV leaflets and, possibly, genes determining distinct BAV morphology. Similarly, BAVc vs. TAV comparison could give insight into the shared vs. differential calcification-related pathways, the impact of aging on aortic valve, and, possibly, also BAV origin.
Nineteen DEGs were shared among all the subgroup pair comparisons, which included genes regulating cell adhesion [ACAN, TIMD4 (T-cell immunoglobulin and mucin domain containing 4), and FCRL5 (Fc receptor-like protein 5)], developmental process [IGLL5 (immunoglobulin lambda-like polypeptide 5), CNTFR (ciliary neurotrophic factor receptor), MYOC (myocilin), and ACAN], and matrix protease MMP9 (gelatinase B). Within the 114 overlapping genes between BAVr vs. TAV and BAVr vs. BAVc intersect (i.e., compartment D on Fig. 6, inset) , there was a common pattern of extracellular matrix-related genes dysregulation, including significant upregulation of inflammatory response genes, serpin protease inhibitors (SERPINA1, SERPINE1), and calcificationrelated genes [BGLAP (osteocalcin), DLL4 (delta-like 4, NOTCH ligand), GFAP (glial fibrillary acidic protein), HBA1/ HBA2 (hemoglobin, alpha), MMP1, and SPP1] in the BAVc and TAV compared with the BAVr group. Interestingly, IPA identified these calcification-related genes as downstream affecters of NOTCH1 signaling pathway. The expression of NOTCH1 itself was not differentially expressed among all the subgroup pair comparisons. Moreover, downregulation of metalloprotease ADAMTS9 (a disintegrin and metallopeptidase with thrombospondin type 1 motif 9) was uniquely observed in BAVr vs. TAV subgroup pair.
The unique pattern of DEGs regulating cardiogenesis and/or heart valve development was also noted between different subgroup pairs. Namely, within 71 DEGs unique to BAVr vs.
TAV there were developmental factors HAND2 (heart and neural crest derivatives expressed 2), EYA1 [eyes absent homolog 1 (Drosophila)], GREM1 (gremlins1), SEMA6B (semaphorin 6B), and cardiac transcription factor GATA4 (GATA binding protein 4). Upregulation of transcription factor TBX20 (T-box 20) was observed uniquely within BAVr vs. BAVc, while upregulation of COL13A1 (collagen, type 13␣1) and downregulation of WNT7A (wingless-type MMTV integration site family, member 7A) were unique to BAVc vs. TAV. Furthermore, increased expression of valve progenitor markers COL2A1 (collagen, type 2␣1), COL11A1 (collagen, type 11␣1), ACAN, and MMP13 (collagenase-3) was observed in both BAVc and TAV compared with BAVr.
DISCUSSION
The present study describes genome-wide differential transcriptome profiling underpinning valvular degeneration in human BAV and TAV using RNA-seq. Differential gene expression profiles were observed among BAV patients, dividing them into two subgroups: those with calcification-predominant disease (BAVc) and those with primarily redundant leaflet degeneration (BAVr). The gene expression pattern of BAVc was found to be more similar to the TAV rather than the BAVr group. Comparative functional analysis of the DEGs revealed the presence of shared and unique genes/pathways between the different subgroup pairs. Dysregulation of extracellular matrix genes and genes regulating cellular adhesions appeared to be a common feature of valvular degeneration in both BAV and TAV. The data obtained from the study provide new insight into the molecular basis of phenotype heterogeneity seen in human BAV disease.
Significant overexpression of ossification and inflammatory response genes was seen in both BAVc and TAV with notable downregulation of the NOTCH1 signaling pathway. This implied the presence of a common terminal pathway in genes regulating valvular calcification in both BAV and TAV. A unique pattern of differential expression of genes controlling cardiac and/or heart valve development was also identified among the subgroups. In particular, downregulation of ADAMTS9 and ACAN was observed in the BAVr compared with the TAV. Furthermore, there was notable downregulation of semaphorins signaling through SEMA6B and SEMA3F (semaphorin 3F) in BAVr and BAVc, respectively, compared with the TAV group. Taken together, these findings indicate the presence of distinct gene expression signatures that mark a different type of valvular degeneration in BAV compared with TAV, supporting the emerging theory that BAV is heterogeneous with respect to molecular events in disease progression (Fig. 7) .
Central to the pathogenesis of human heart valve disease is the disruption of the normal valve homeostatic process, which leads to abnormal leaflet architectural organization and disproportionate alteration of extracellular matrix constituents (26) . Imbalance of protease, MMP, and ADAMTS expression can accelerate the leaflet degradation process by changing the structural composition of the valve matrix, leading to pathological remodeling, valvular degeneration, and subsequent valve dysfunction. In this study, four MMPs were differentially expressed, namely MMP1, MMP7, and, notably, MMP9 and MMP13, but not MMP2. The matrix remodeling enzyme gene Fig. 6 . Venn diagram showing overlap in the number of DEGs between analyzed subgroups, providing insight to unique and common genes that were important in the pathogenesis of valvular degeneration among subgroups. The rationale is that DEGs between the BAVr vs. TAV group would consist of genes that were not only responsible for BAV leaflet redundancy/prolapse or calcification in TAV but also BAV development, while the BAVr vs. BAVc comparison would highlight genes responsible for the different form of valvular degeneration in BAV leaflets and, possibly, genes determining distinct BAV morphology. Similarly, BAVc vs. TAV comparison could give insight to the shared vs. differential calcification-related pathways, the impact of aging on aortic valve, and, possibly, also BAV origin. Gene lists of compartments A-G (inset) are summarized in Table 6 .
MMP13 was found to be the most highly upregulated gene in the degenerative TAV and BAVc groups compared with the extremely low expression in BAVr, suggesting its importance in valvular calcification.
MMP13 is a major collagenase that plays an important role during cardiogenesis and heart valve development, with catalytic activity predominantly on type II collagen and aggrecan matrix constituents (2, 5) . In degenerative bone disease models, such as osteoarthritis, MMP13 facilitates chondrocyte terminal differentiation by ensuring concerted upregulation of RUNX2, VEGF (vascular endothelial growth factor), and active ␤-catenin signaling pathways, which induce osteoblastogenesis and new bone formation (2) . Given the presence of a shared molecular mechanism regulating heart valve, cartilage, and bone development, which can be reactivated in adult valve disease (18) , it is conceivable that MMP13 induces calcific valve phenotype in either BAV or TAV through a similar mechanism. Significant dysregulation of MMP9 was commonly observed among all three subgroup comparisons. Normally involved in type IV collagen and elastin degradation, an increase in MMP9 activity had been detected in vascular pathologies, such as abdominal aortic aneurysms, and in diseased BAV compared with diseased or normal TAV leaflets (17) . The current study shows that a significant increase in MMP9 activity can be observed in heavily calcified leaflets of either TAV (highest activity) or BAV origin (BAVc) compared with the lower expression in the minimally calcified BAVr (lowest activity) group. Consistent with previous studies (8, 10) , this indicates the presence of enhanced proteolytic/elatolytic activity of MMP9 in calcified leaflets in both BAV and TAV. As inflammatory cells (e.g., macrophages and neutrophils), but not valvular interstitial cells, are prevalent MMP9 producers, this indirectly implies a higher degree of inflammation in heavily calcified and stenotic leaflets compared with redundant and regurgitant leaflets, which is in support of previous study (10) . Indeed, inflammatory infiltration of activated macrophages and T-cells has been reported in human stenotic aortic valve (22, 23) . Notably, no significant differential expression of tissue inhibitor of MMPs was observed within the dataset, suggesting the presence of net proteolytic activity of MMPs in valve disease pathogenesis.
The current study provides further evidence that BAVrelated calcification occurs in a similar fashion to that seen in patients with calcific TAV, where an active biological process involving inflammation, oxidation, angiogenesis, extracellular matrix remodeling/fibrosis, and atherosclerosis-like ectopic calcification with bone-like mineralization of the aortic side of the valve leaflet exists (3). Shared upregulation of osteogenic gene programs was observed between the BAVc and TAV groups, which included upregulation of bone-specific tran- Table 6 Fig. 6 Group Genes, n List of Genes   A  71  ACE, ADAMTS9, ADCYAP1, ALOX5AP, AMPD1, AOAH, APOC2, ATP6V0D2, BMP3, CCL4, CD3E, CD52, CHAD, CHST1,  CHST15, CHST9, CLU, CPEB1, CR1, EBF2, EMR1, EPB41L4B, EYA1, FAIM3, FCRL3, FMO3, GATA4, GBP3, GREM1,  HAND2, HLA-DOB, HMOX1, IL1RN, ITGAL, KIAA1217, KIRREL3, KLK4, LAPTM5, LBH, LTB, LYZ, MATK, MFAP5,  MS4A1, MYO1G, NFIA, NTRK2, NUP210, PLA2G2D, PLAU, PNOC, PPBP, RBP1, S100B, SCUBE1, SDS, SEMA6B,  SLC14A1, SLC44A3, SLC6A1, SLC7A2, SMOC1, SMOC2, SPIB, SRGN, TCEAL2, TM4SF19, TMEM119, TMEM56,  TREM2, TRHDE  B  91  ACTG2, ADAMTS16, ADCYAP1R1, ALDH3A1, ANGPTL7, AOC2, ASPN, C2orf88, C4A, C4B, C5AR1, CBLN1, CCL8,  CD300C, CD93, CECR2, CHGA, CLDN10, CNTN1, COL9A1, CPXM1, CTHRC1, CYP26A1, DOK6, ENTPD2, ERBB3,  FAM123A, FAP, FCGBP, FCGR3A, FCGR3B, FCN1, FZD8, GADL1, GNLY, GPR84, GPR88, HAPLN3, HIST2H2BF,  IFITM10, IGFBP2, IGFN1, ITLN1, JUNB, KIF26A, KISS1, LDLR, LGI4, LILRB2, MATN2, MEIS2, MEPE, MET, MYH14 GALNT3, GFAP, GJB2, GPIHBP1, GPR68, GZMB, HBB, HMGCLL1, IBSP, IFI30, IGSF10, IL1RL1, IL21R, IRF4, ISM1,  KCNJ15, KCNK2, KCNN4, KIAA1199, KIF1A, LAMC3, LCNL1, LRRC15, MAPT, MAT1A, MED12L, MMP1, MMP13,  MYH10, NDUFA4L2, NELL2, NPPC, NSG1, NWD1, OGN, PDZRN4, PIM2, PKP2, PLAUR, PLCH1, PLVAP, POU2AF1,  PRND, PTP4A3, RGS16, RIMS4, S100A9, SCN7A, SDC1, SERPINA1, SERPINE1, SFRP1, SLAMF6, SLAMF7, SLC11A1,  SLC2A5, SLC6A20, SLPI, SOX10, SP7, SPOCK3, SPP1, ST14, STMN2, TDO2, TM4SF18, TMEM132C, TMEM200A, TNC,  TNXB, TP53I11, TREM1, TSPAN11, VCAM1  E  20  A2M, ACP5, APLN, CCL19, CHI3L2, CHIT1, CMA1, CXCL9, GLRX, GPHA2, GZMK, HLF, ITGAX, MMP7, MMRN1,  MTRNR2L8, MUC20, RASSF6, SGCA, VMO1  F  41  ABCC9, ABP1, ACTC1, ADAM12, AIF1L, ALDH1A1, BMPER, C1QTNF8, C7, CCKAR, CHL1, CHRDL1, COCH, CPA3,  DDX11, DES, DPYSL4, FAM107A, FNDC1, FOS, FOSB, GFRA1, GSTT1, HLA-DQA1, HS3ST1, JUN, LIFR, NKAIN2,  NOS3, PAX8, PI16, PLIN4, PTPRB, RPSAP58, SCG2, ST6GALNAC1, SYNPO2, THNSL2, TPSAB1, TRDN, WNT9B  G  19  ACAN, ATP1A2, CD79A, CNTFR, CTSE, DERL3, FCRL5, HBA1, HBA2, HLA-DRB5, IGJ, IGLL5, MMP9, MYOC,  PPP1R1B, PTGDS, RP11-1280I22.1, SCARA5, TIMD4 scription factor SP7 (osterix), bone differentiation marker IBSP and BGLAP, NOTCH ligand DLL4, MMP1 and MMP9 proteases, and bone biomineralization marker SPP1, many of which interact with or are known as part of the downstream signaling pathway of the transcription factor NOTCH1 (9, 29) . In fact, the NOTCH1 signaling pathway appeared to be downregulated in these calcific leaflets, probably mediated through the reduction in NOTCH1-mediated repression of Runx2 activity (29), a central transcriptional regulator of osteoblast cell fate, which resulted in the observed upregulation of SP7, BGLAP, and SPP1 activities (Fig. 8) . This is an interesting finding as missense and frameshift mutations of NOTCH1 gene, leading to haploinsufficiency, are associated with human BAV, as well as calcific aortic stenosis in both BAV and TAV patients (7, 11) . Notably, analysis of the RNA-seq data demonstrates that expression of the NOTCH1 itself was not differentially expressed in the BAVc and TAV compared with the BAVr groups. It is possible that dysregulation of NOTCH1 expression could have occurred earlier at the onset the disease process, but not at the terminal disease state, or that there may be other upstream regulators that cross talk with the signaling pathway downstream of NOTCH1. Nevertheless, the present data suggest that NOTCH1-related terminal signaling pathway may be a common final pathway in aortic valve calcification, although further study is required to elucidate the initial molecular event that may have triggered the initiation of calcification process in both BAV and TAV. It is also worth noting that the TAV patients with severe degenerative aortic stenosis were significantly older at the time of surgery compared with the BAV group, including those with a similar condition (BAVc group). This is not surprising as BAV is associated with increased mechanical stress on the abnormal valve structures, contributing to an accelerated "wear and tear" and progression to aortic stenosis at a younger age group among affected patients (13) . Meanwhile, physiological studies on an aging human heart have shown that aging resulted in the characteristic loss of myocytes, enlargement of the remaining myocytes (cardiac hypertrophy), and cardiac Fig. 7 . Proposed mechanism or pathway leading to the development of structural valvular degeneration in BAV vs. TAV. The pathogenesis of BAV is largely undetermined, although gene mutations and other factors in utero likely contribute to its development. Intrinsic valvular degeneration and dysfunction are the most common complications of BAV disease, which phenotypically ranges from calcific aortic stenosis to redundant or prolapsing regurgitant leaflets. While the initiating factor that drives the onset of valvular degeneration remains to be elucidated, data from the present RNA-seq study show that dysregulation of extracellular matrix genes and genes regulating cellular adhesions appeared to be a common feature of valvular degeneration in both BAV and TAV. Specifically, BAV with predominantly regurgitant phenotype demonstrate downregulation of ADAMTS9 and aggrecan. Meanwhile calcific BAV and TAV showed shared upregulation of inflammatory and calcification related pathway, including shared downregulation of NOTCH1-related terminal pathway. These findings suggest that diverging molecular mechanisms underpin phenotype heterogeneity of valvular degeneration in BAV disease, while shared mechanisms leading to calcification may be present in both BAV and TAV.
. Gene lists comprising the different Venn diagram compartments (A-G) as depicted in
fibrosis (27) , a process also affecting the degenerating aortic valve. At the molecular level, aging resulted in major alterations of cardiac gene expressions in a murine heart model, particularly induction of the stress response pathway, reduced expression of genes involved in energy metabolism, and induction of genes encoding cellular structural proteins and fibrosis (27) . Therefore, it is possible that the observed difference in the RNA-seq data between the BAVc and TAV groups (Supplementary Table S4 ), particularly among the differential expression of genes encoding structural and matrix proteins, may in part be due to the direct impact of aging on the aortic valve leaflets.
While many pathways regulating calcific aortic stenosis have been described, genetic and molecular factors leading to intrinsic BAV leaflet redundancy, prolapse, and subsequent development of aortic regurgitation remain mostly unknown. Recently, adult murine models with Adamts9 haploinsufficiency have been shown to develop aortic valve thickening, enlargement (redundancy), and even malformation, as well as ascending aortic wall anomalies (14) . Important in cardiovascular development and/or allostasis, the proteoglycanase ADAMTS9 is involved in cleavage of large proteoglycan aggrecan (ACAN) and versican, two important components of human valve matrix. Interestingly, downregulation of ADAMTS9 and ACAN was observed in the BAVr compared with the TAV. Furthermore, lower expression of valve progenitor markers COL2A1 and COL11A1 was observed in the BAVr compared with the BAVc and TAV groups. This implies synthesis of collagen, a structural protein, might be downregulated in the BAVr group, giving the aortic valve a lower tensile strength. Over time, this structural abnormality likely contributes to progressive leaflet laxity, redundancy, and chronic valvular dysfunction.
Human genetic studies are beginning to provide evidence that developmental pathways important in valvulogenesis also contribute to adult valve disease (18) . This is supported by the current RNA-seq study, which demonstrates unique patterns of dysregulation of fetal genes important in cardiac and heart valve development among the study subgroups. Of particular interest is unique upregulation of TBX20 in BAVr compared with the BAVc group, as well as unique downregulation of SEMA6B and SEMA3F in BAVr vs. TAV and BAVc vs. TAV groups, respectively. These findings reflect the multigenic complexities of BAV development and progression.
Limitations
To facilitate interpretation of RNA-seq data, this study relies heavily on the available bioinformatics tools and literature, which may create some limitations since many gene functions and molecular pathways are yet to be elucidated. Furthermore, the current study is limited by the unavailability of structurally normal TAV as the ideal comparative control group, and therefore, a number of important genes related to the anomaly itself could probably be missed during the analysis. The study is also limited by the relatively small sample size of the RNA-seq group, which was partly contributed by the difficulty in obtaining a sufficient quantity of high-quality total valve RNA, especially from heavily calcified leaflets. Moreover, wide variability was observed among a number of samples within each subgroup on RT-qPCR data. This may reflect the fact that each individual sample, even those within the same subgroups, might be at a different stage of disease process. Additionally, data on isoform difference were not available from our RNA-seq analysis using the Seq-Monk platform. As differential isoform expression may influence the ultimate disease expression and be responsible for phenotype heterogeneity seen in BAV disease, future study on isoform level expression profiling is therefore warranted. Finally, the current study analysis was limited to the end-stage form of the valve disease process, while the initiating factor that drives the disease onset remains to be elucidated. It is indeed important to recognize that RNA-seq study demonstrates transcript levels of a given cell or tissue at one specific time point only, i.e., at the time when the study is conducted, which in this case is at the terminal end of the disease process. Since much of the pathology might have arisen from very different RNA levels that were present earlier in the disease course, the transcript levels measured during the current RNA-seq experiment are likely to be a consequence of an earlier event, rather than causative. Fig. 8 . Alteration of the NOTCH1 terminal signaling pathways in severe calcific aortic stenosis, as detected by the RNA-seq study. A simplified version of the NOTCH1 downstream signaling pathway. It is postulated that the NOTCH1 signaling pathway is downregulated in these calcific leaflets, both in BAV and TAV cases, probably mediated through the reduction in NOTCH1-mediated repression of Runx2 activity. This in turn results in the observed upregulation of SP7 (osterix), BGLAP (osteocalcin), and SPP1 (osteopontin) activities, as demonstrated by the RNA-seq study (red arrows). At the cellular level, these signaling alterations stimulate osteogenic differentiation of the aortic valvular interstitial cells, bone formation, and leaflet calcification, resulting in clinical aortic valve stenosis. These alterations of the NOTCH1 terminal signaling pathway were observed in both BAV and TAV leaflets, suggesting that it may be a common final pathway in aortic valve calcification. Further study is, however, required to elucidate the upstream molecular event that may have triggered the initiation of calcification process in both BAV and TAV. Msx, homeobox 7; Hes and Hey genes are NOTCH1 targets; ALP, alkaline phosphatase, Dlx5, distalless homeobox 5; BMPs, bone morphogenic proteins.
Conclusions
This study presents the first global comparative transcriptome profiling of human BAV disease compared with TAV using RNA-seq. The study demonstrates the relatively close resemblance of gene expression patterns of calcified human BAV and calcified human TAV leaflets, with shared upregulation of inflammatory pathways and downregulation of NOTCH1-related signaling, suggesting a common mechanism of calcific leaflet degeneration in both BAV and TAV. Dysregulation of ADAMTS9 and ACAN likely contributed to leaflet redundancy or prolapse in BAV disease. This study has also identified the unique dysregulation of fetal gene programs, including the potential role of semaphorins in the development of BAV and its related aortopathy. Understanding of genetic pathways leading to valvular degeneration is important, as it is a precursor of overt clinical valve dysfunction and will facilitate the development of new therapies that halt progressive leaflet degeneration, with the ultimate goal of reducing the overall health burden of human BAV disease.
